Every letter we have printed

Hydration is the dominant short-term error term in most of these methods and the least controlled. A standardised fasting and fluid protocol before scanning would tighten these datasets more than any statistical technique.

Absorptiometry divides tissue into three compartments and calls one of them lean, which includes water, organ and connective tissue as well as muscle. A fall in lean mass is not the same finding as a fall in muscle, and the reporting almost always translates one into the other.

Publishing the individual-level scatter rather than the group means would transform this literature. The means are compatible with several very different underlying distributions and the scatter would distinguish them immediately.

Light exposure is trivially controllable and almost never controlled. A clear vial on a shelf near a window is running a photostability study nobody designed, and the effect is real for several residue types.

The diluent is the variable nobody records. Bacteriostatic and plain water produce solutions with different chemistry and different in-use expectations, and accounts of stability in this market rarely state which was used.

The most useful thing this department could publish is a plain statement of what is and is not known about in-use stability for this class, with the sources. The absence of such a statement is why the folklore has filled the space.

Deamidation at asparagine is the dominant route for several of these sequences and it is strongly pH dependent, which makes the reconstitution diluent a stability decision rather than a convenience one. Bacteriostatic water is not neutral in this respect and very few people treat it as a variable.

Designing the error out is more effective than warning about it, which is the settled conclusion of every human-factors literature. In this market nobody controls the design, so the only available lever is the weakest one.

The error nobody counts is the one made in the vial rather than the syringe: vigorous shaking during reconstitution. It does not change the arithmetic and it can change what is in the solution, and the correct instruction is to swirl and wait.

Sharps disposal is not an afterthought and the article treats it as one. A rigid container, obtained before it is needed rather than after, is the whole of the advice, and it belongs at the start of the sequence rather than at the end.

Single-use means single-use, and the reason is mechanical as much as microbiological. A needle blunts on first insertion, and the second insertion is measurably rougher. This is one of the few places where the practical argument and the aseptic argument agree completely.

In our hands the useful pairing is a hydrophobicity separation for the bulk figure and a charge-based one for the degradation question. They answer different questions and we stopped pretending either was a check on the other. Once we said that out loud the reporting became much simpler.

Ion-exchange deserves a place beside size-exclusion in your list of second principles. Deamidation shifts charge without shifting mass or hydrophobicity appreciably, so it is close to invisible in reversed phase and obvious on a charge-based separation. For an ageing peptide it is the question worth asking.

A buyer sees a badge as a promise about the vial arriving next week. A service sees it as a receipt for work performed. Neither party is being unreasonable and the artefact sitting between them supports both readings.

There is an argument that the badge is aimed at the seller rather than the buyer: it exists so that suppliers who test can distinguish themselves from those who do not. If that is the purpose, it is a poor consumer instrument being asked to do a trade-signalling job.

Your description of gradient slope as the dominant variable matches our experience, but the way to express it is in per cent organic per column volume rather than per minute. Two laboratories running the same programme on different column dimensions are not running the same gradient, and the minute figure hides that.

Injection solvent belongs on your list. A sample dissolved in something stronger than the starting mobile phase will distort the leading peaks before the gradient has begun, and the distortion is worst for exactly the early-eluting impurities the method is meant to resolve. It costs nothing to state and almost nobody does.

The signature block is not decoration. A named analyst with a role, over a determination date, is a person who can be asked a question. A scanned signature with no name under it is an image.

Appearance is the most under-rated line on the page. It is a genuine observation, it is free, and a cake described as white when the vial in front of you is faintly yellow tells you something has happened between the two. Everything else on the certificate requires an instrument to argue with.

The question I have learned to ask first is who commissioned the test. A certificate paid for by the seller, a certificate paid for by the buyer and a certificate paid for by a third party at the seller’s request are three different documents, and only one of them names the arrangement on its face.

Desensitisation kinetics differ between ligands at the same receptor, which is a well-established property of this family and almost absent from the popular account. A compound that resists desensitisation behaves differently over weeks regardless of its acute potency.

Species-matched receptor is the minimum condition for a potency comparison to be meaningful, and several widely circulated tables mix figures obtained on receptors from different organisms. The mixing is not visible in the table.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

Access to a tissue is as important as the presence of a receptor in it, and molecules of this size do not cross every barrier freely. A receptor that cannot be reached is not part of the mechanism.

The GIP contribution remains genuinely unsettled and your piece says so, which is more than most coverage manages. Agonism and antagonism at that receptor have both been argued to produce benefit, and a mechanism that works either way round is a mechanism that has not been demonstrated.

Reported rates depend heavily on whether the study asked or waited to be told. Solicited and unsolicited adverse event collection produce different numbers from the same population, and the method is buried in the supplement.

A short observation on reporting. Percentages without denominators are common in secondary coverage of this literature, and a rate quoted from a study arm of forty people is being read as though it came from four thousand.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

Any account of maintenance that does not mention what happens to muscle over the same period is incomplete, and most do not. The composition literature and the maintenance literature are written by different people and rarely cite each other.

An argument for writing about this at all: people are making long commitments now, on information collected over shorter periods, and a publication that keeps saying how long the evidence runs is doing something useful even when it has nothing new to report.

The phrase lack of efficacy conceals two different things: no effect at all, and an effect that stopped being worth the effort. They have different implications and they are recorded under one heading.

Nobody asks about the reasons for continuing, which are at least as interesting. A population that has stayed with something for two years has revealed a preference, and understanding it would inform the discontinuation question from the other side.

The most honest account I have read simply said the person could not remember deciding. That is a real answer and there is nowhere to record it, so it becomes a missing value.

The central component acting through the brainstem is often left out of popular accounts, which then explain nausea entirely in terms of the stomach. Both routes contribute and they predict different things about how quickly the effect settles.

Adaptation over weeks is the feature that most needs explaining and the one with the least mechanistic work behind it. Everything published addresses the acute effect, which is the part that resolves on its own.

What proportion of participants reached the target dose is a single number reported in most of these papers and quoted in almost none. It is the most direct statement of tolerability the study contains.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

A short thank you for the reference desk, which I use more often than the articles. Somebody has clearly spent a great deal of time on material that will never be anybody’s headline.

Recent strenuous activity moves several markers into ranges that look alarming and resolve in days. Anybody arranging their own testing should record what they did the day before, and almost nobody does.

Haemolysis is the commonest artefact and it is visible to the laboratory, which is why the comment on the report matters more than any individual value. Several analytes are unusable in a haemolysed sample and the report says so if you read it.